Victory Capital Management Inc. Lowers Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Victory Capital Management Inc. reduced its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 9.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,428 shares of the company's stock after selling 10,504 shares during the quarter. Victory Capital Management Inc.'s holdings in Moderna were worth $2,989,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the period. Theleme Partners LLP boosted its holdings in shares of Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after purchasing an additional 72,028 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after purchasing an additional 171,774 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Moderna in the 4th quarter valued at $163,833,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $34.15 on Monday. Moderna, Inc. has a one year low of $23.15 and a one year high of $125.68. The business's 50-day simple moving average is $28.77 and its 200 day simple moving average is $30.41. The company has a market cap of $13.21 billion, a P/E ratio of -3.91 and a beta of 1.84.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The business had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same quarter in the previous year, the firm posted ($3.07) earnings per share. The company's revenue was down 35.3% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. Barclays reiterated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. William Blair reissued a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Morgan Stanley lowered their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Cowen initiated coverage on Moderna in a research report on Sunday, July 13th. They set a "hold" rating for the company. Four analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $46.11.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.